12:00 AM
 | 
Jun 09, 2014
 |  BC Week In Review  |  Company News  |  Deals

Labrys Biologics Inc., Teva deal

Teva will acquire Labrys for $200 million in cash up front plus up to $625 million in developmental milestones. Labrys' sole compound is LBR-101, which is in Phase IIb testing to treat and prevent chronic and...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >